Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia
- 530 Downloads
The number of anticancer drugs available in oral formulation has risen sharply in the past few years and this is expected to continue to increase over the next several decades. For patients, the convenience of self-administration constitutes a major benefit associated with oral therapy. For clinicians, however, the transition from parenteral to oral therapy has resulted in concerns about adherence to therapy, its monitoring, and its effects on clinical outcomes. Several studies have demonstrated that imatinib is effective at improving overall survival and/or recurrence-free survival in patients with gastrointestinal stromal tumors and chronic myeloid leukemia (primary and metastatic disease). Despite the survival benefit and the favorable toxicity profile of imatinib, however, adherence to imatinib remains poor. Herein, we review the evidence showing the effects of nonadherence on patient outcomes as well as data indicating that adherence to imatinib (and oral anticancer therapy in general) is suboptimal. We also highlight factors that may contribute to nonadherence and suggest key steps that can be implemented by the multidisciplinary medical team to overcome the daily challenges of adherence. Improving adherence to imatinib depends on open communication and comprehensive patient education. All of this is essential to maximize benefits from therapy and improve clinical outcomes for our patients.
KeywordsGastrointestinal stromal tumor GIST Chronic myeloid leukemia CML Imatinib Adherence
Medical writing and editorial assistance were obtained from Michele Jacob, PhD, and Larry Rosenberg, PhD, at Evidence Scientific Solutions.
Funding was provided by Novartis Pharmaceuticals Corporation.
Conflicts of interest
The authors do not have any financial relationships to disclose.
- 8.Weingart SN, Brown E, Bach PB et al (2008) NCCN task force report: oral chemotherapy. J Natl Compr Cancer Netw 6(suppl 3):S1–S14Google Scholar
- 11.Demetri GD, von Mehren M, Antonescu CR et al (2010) NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Cancer Netw 8(suppl 2):S1–S41, quiz S42–S44Google Scholar
- 12.Blay JY, Le Cesne A, Ray-Coquard I et al (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25:1107–1113PubMedCrossRefGoogle Scholar
- 14.von Mehren M, Heinrich MC, Joensuu H et al. (2011) Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT + gastrointestinal stromal tumors (GIST). J Clin Oncol 29(15 suppl): Abstract 10016Google Scholar
- 16.Dematteo RP, Ballman KV, Antonescu CR et al (2009) On behalf of the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097–1104PubMedCrossRefGoogle Scholar
- 18.National Comprehensive Cancer Network (NCCN) (2012) NCCN clinical practice guidelines in oncologyTM: Soft tissue sarcoma. National Comprehensive Cancer Network(R). Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 21 Sep 2012
- 20.Halpern R, Barghout V, Zarotsky V et al (2009) Costs and utilization associated with imatinib adherence in patients with chronic myeloid leukemia or gastrointestinal stromal tumors. J Clin Outcomes Manag 16:215–223Google Scholar
- 24.Ray-Coquard IL, Bin Bui N, Adenis A (2010) et al. Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study. J Clin Oncol 28(15 suppl): Abstract 10032Google Scholar
- 26.Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). J Clin Oncol 24(18S suppl): Abstract 6119Google Scholar
- 27.Feng W, Henk H, Thomas S et al. (2006) Compliance and persistency with imatinib. J Clin Oncol 24(18S suppl): Abstract 6038Google Scholar
- 30.Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626–632PubMedCrossRefGoogle Scholar
- 35.O'Brien SG, Guilhot F, Goldman JM et al. (2008) International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood (ASH Annual Meeting Abstracts) 112: Abstract 186Google Scholar
- 36.Baker LH, Rankin CJ, Blanke CD et al. (2011) Long-term follow-up of SWOG S0033, a phase III randomized intergroup trial assessing imatinib mesylate at two dose levels in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST). Connective Tissue Oncology Society Annual Meeting Abstracts: Abstract 24Google Scholar